Flow Cytometric Immunophenotyping of Adult T-Cell Leukemia/Lymphoma Using CD3 Gating
|
|
- Francis Logan
- 6 years ago
- Views:
Transcription
1 Hematopathology / ATLL IMMUNOPHENOTYPING USING CD3 GATING Flow Cytometric Immunophenotyping of Adult T-Cell Leukemia/Lymphoma Using CD3 Gating Taiji Yokote, MD, 1 Toshikazu Akioka, MD, 1 Satoko Oka, MD, 1 Satoshi Hara, MD, 1 Kichinosuke Kobayashi, MD, 1 Hideto Nakajima, MD, 1 Takeshi Yamano, MD, 1 Toshiyuki Ikemoto, PhD, 3 Akira Shimizu, MD, 3 Motomu Tsuji, MD, 2 and Toshiaki Hanafusa, MD 1 Key Words: Adult T-cell leukemia/lymphoma; Flow cytometry; Immunophenotyping; CD3 gating DOI: /KEN4MXM5Y9A1GEMP Abstract Adult T-cell leukemia/lymphoma (ATLL) is a lymphoproliferative neoplasm of helper T lymphocytes caused by human T-cell leukemia virus type-1 (HTLV- 1). The disease was first described in Kyushu, in southwestern Japan, and most frequently occurs in endemic areas, such as Japan, the Caribbean basin, West Africa, Brazil, and northern Iran. ATLL is essentially a disease of adults, characterized clinically by generalized lymphadenopathy, hepatosplenomegaly, skin lesions, and hypercalcemia. The prognosis of most patients is quite poor, with a median survival time of only 13 months, even if multiagent combination chemotherapy is given. In the present study, flow cytometric immunophenotyping with CD3 gating was performed on 30 samples from 26 patients who had been given a diagnosis of ATLL. The records of these patients also were reviewed retrospectively. In 14 of the 30 samples, an abnormal CD3 low T-cell population was distinguishable from the normal T-cell populations by flow cytometric analysis. Herein we report a novel strategy for flow cytometric immunophenotyping of ATLL facilitated by CD3 low gating. Materials and Methods Case and Control Samples We retrospectively reviewed all cases of ATLL diagnosed at the Osaka Medical College, Osaka, Japan, from January 1998 to January Diagnosis of ATLL was based on the presence of an antibody positive for anti HTLV-1, histologic identification of lymphoproliferative disease of peripheral T-cell origin, and confirmation of monoclonal integration of the HTLV-1 proviral genome by Southern blot. This analysis yielded 30 samples from 26 patients, consisting of 20 peripheral blood samples, 3 bone marrow aspirate samples, 5 lymph node samples, 1 pleural effusion sample, and 1 bronchoalveolar lavage fluid (BAL) sample. The 26 patients (14 men and 12 women) had a mean ± SD age of 60.3 ± 11.8 years. Because ATLL is a clinically heterogeneous disease, the cases were classified in 4 subtypes 1 : acute-type ATLL, 19 (73%); chronic-type ATLL, 1 (4%); lymphoma-type ATLL, 3 (12%); and smoldering ATLL, 3 (12%). All cases exhibited 5% or more abnormal ATLL cells in each specimen, including cells with hyperlobated nuclei (flower cells) or irregular nucleolar contours. For comparison of CD3 fluorescence intensity of normal T cells with that of ATLL cells, 15 normal peripheral blood samples obtained from healthy volunteers were studied. The mean ± SD age of the healthy volunteers was 41.5 ± 10 years (range, years). Flow Cytometry Sample Preparation and FACS Acquisition For preparation of the cell suspension, lymph node samples were minced with scissors and filtered through a 50-µm Am J Clin Pathol 2005;124: DOI: /KEN4MXM5Y9A1GEMP 199
2 Yokote et al / ATLL IMMUNOPHENOTYPING USING CD3 GATING mesh nylon filter. Peripheral blood samples, bone marrow aspirates, and pleural effusion and BAL samples were treated with EDTA or heparin for anticoagulation and processed using a lysed whole blood technique using fluorescence-activated cell sorting (FACS) lysing solution (Whole Blood Lysis Reagent, Coulter, Fullerton, CA). All samples (regardless of origin) were washed twice in phosphate-buffered saline (PBS) and resuspended in PBS at a concentration of approximately cells per milliliter. Samples were stained dually with fluorescein isothiocyanate (FITC)-conjugated CD2 (MT910, DAKO, Carpinteria, CA), CD4 (T4, Coulter), CD28 (COLT2, Nichirei, Tokyo, Japan), and phycoerythrin-cyanine 5.1 (PC5)-conjugated CD3 (UCHT1, Coulter) for 30 minutes at 4 C. Negative control samples were stained with FITC-conjugated rat antihuman immunoglobulin (LODNP1, Coulter) for 30 minutes at 4 C. Case samples also were stained dually with phycoerythrinconjugated CD5 (UCHT-2, Pharmingen, San Diego, CA), CD7 (My7, Coulter), CD8 (DK25, DAKO), CD25 (2A3, Becton Dickinson, San Jose, CA), CD45RO (UCHL-1, Becton Dickinson), CD45RA (2H4, Coulter), CD62L (TQ1, Coulter), HLA-DR (L243, Pharmingen), and PC5-conjugated CD3 (UCHT1, Coulter) for 30 minutes at 4 C. Negative control samples were stained with phycoerythrin-conjugated rat antihuman immunoglobulin (LODNP1, Coulter) for 30 minutes at 4 C Image 1. All samples were rinsed twice in PBS and analyzed on a FACScan flow cytometer (EPICS XL, Beckman Coulter, Fullerton, CA) using System II software, version 3.0 (Beckman Coulter). At least 10,000 cells in total were analyzed. FACS Analysis A CD3 gating strategy was used to identify ATLL cells. All samples were analyzed in the side scatter (SS) vs CD3 histogram mode. In the abnormal cell samples, CD3 peak fluorescence intensity below 10 on the log scale was defined as CD3 low, an A 1,000 CD3-PC5 A C ,024 SS B 1, ,024 SS Image 1 Representation of flow cytometric histograms for adult T-cell leukemia/lymphoma samples. A, Bivariate histogram CD3/side scatter (SS). Gate A shows the CD3 medium population. B, Bivariate histogram CD3/SS. Gate A shows the CD3 low population. PC5, phycoerythrin-cyanine 5.1. B CD3-PC5 D A C B intensity between 10 and 100 as CD3 medium, and an intensity more than 100 on the log scale as CD3 high. The cells in the CD3 low and CD3 medium population regions were acquired (gate A), and this procedure was defined as CD3 low and CD3 medium gating, respectively. Cells with overlap of less than 50% with the isotype control or with more than a 30% positive distinct population above the isotype control were defined as positive. The expression levels of T cell associated antigens (CD2, CD3, CD4, CD5, CD7, CD28, CD45RA, CD45RO, and CD62L), activated antigen (CD25), and HLA-DR in positive cells were evaluated. Immunohistochemical Analysis Lymph node slides were obtained from tissue samples fixed with 10% buffered formalin and embedded in paraffin. Peripheral blood samples and bone marrow aspirates were smeared manually. BAL samples were processed by application of Cytospin (Shandon, Pittsburgh, PA) to the fluid. Immunohistochemical analysis of the peripheral blood, bone marrow aspirate, lymph node, and BAL slides was performed using CD7 (titrated at 1:20; DK24, DAKO), CD4 (titrated at 1:20; MT310, DAKO), and CD8 (titrated at 1:20; DK25, DAKO) monoclonal antibodies, using a modified avidin-biotinperoxidase procedure with 3,3'-diaminobenzidine (Sigma Chemical, St Louis, MO) as the chromogen. A negative control experiment was performed for each sample using normal rabbit immunoglobulin fraction (DAKO), and a positive control experiment was performed using lymphocytes from peripheral blood smears from healthy volunteers, using the CD7, CD4, and CD8 monoclonal antibodies as described. The percentage of abnormal cells, such as ATLL cells, was determined from the CD7, CD4, and CD8 immunohistochemical analysis. Statistical Analysis Associations between the gating procedure and CD3 fluorescence intensity were tested using a Kruskal-Wallis test and a Bonferroni-corrected Mann-Whitney U test for unrelated variables. The mean values and their standard deviations, the median, 25th and 75th percentiles, and range were calculated for each variable. P values of.017 or less were considered statistically significant. Associations between the gating procedure and immunophenotyping also were tested using a Fisher exact test, as determined by expected frequencies of variables in 2 2 tables. A P value of less than.05 was used as the criterion for statistical significance. Statistical analyses were performed using SPSS 12J software (SPSS, Tokyo, Japan). Results CD3 Populations CD3 expression was positive in abnormal cells, but the CD3 fluorescence intensity showed 2 patterns. Of the 30 samples 200 Am J Clin Pathol 2005;124: DOI: /KEN4MXM5Y9A1GEMP
3 Hematopathology / ORIGINAL ARTICLE from 26 patients, 14 samples contained a CD3 low population and 16 contained a CD3 medium population. Figure 1 shows the fluorescence intensity for the CD3 low (3.94 ± 2.6) and CD3 medium (26 ± 12) populations and for the normal T-cell population from healthy volunteers (15.6 ± 2.8, control population). Statistically significant differences in the mean fluorescence intensity were observed between the CD3 low population and either the CD3 medium or control population (P <.001). The mean fluorescence intensity of the CD3 low population was significantly lower than that of the control population (P <.001), but no statistically significant difference was observed between the mean fluorescence intensities of the control and CD3 medium populations (P =.037). CD3 Gating The histogram containing the CD3 medium population was separated into 3 categories: CD3 medium population (gate A), granulomonocytes (gate B), and mature B lymphocytes and precursor cells (gate C). The CD3 medium population showed the highest CD3 fluorescence intensity and a low SS signal. Granulomonocytes showed negative CD3 fluorescence intensity and the highest SS signal, and the mature B lymphocytes and precursors showed negative CD3 fluorescence intensity and a low SS signal. Hence, the CD3 medium population was easily distinguishable from granulomonocytes and mature B lymphocytes and precursor cells based on the CD3 and SS signals. By using this approach, the CD3 medium population was identified by gating, and immunophenotyping was performed. In contrast, the histogram containing the CD3 low population was separated clearly into 4 categories: the CD3 low population (gate A), granulomonocytes (gate B), mature B lymphocytes and precursor cells (gate C), and T lymphoblasts and T lymphocytes (gate D). The CD3 low population showed low CD3 fluorescence intensity and a low SS signal, the granulomonocytes showed negative CD3 fluorescence intensity and the highest SS signal, the mature B lymphocytes and precursor cells showed negative CD3 fluorescence intensity and a low SS signal, and the mature T lymphocytes and T lymphoblasts showed the highest CD3 fluorescence intensity and a low SS signal. Hence, similar to the CD3 medium population, the CD3 low population was easily distinguishable from other cells based on the CD3 and SS signals. Following identification, immunophenotyping of the CD3 low population was performed. Flow Cytometric Analysis Table 1 and Table 2 give the results of flow cytometric analysis of each specimen. This analysis showed aberrant T- cell antigen loss or reduced expression in 6 cases (38%) in the CD3 medium population and in 14 cases (100%) in the CD3 low population. A reactive or inconclusive phenotype was apparent in 12 cases (75%) in the CD3 medium population and in 1 case (7%) in the CD3 low population. Loss of CD7 was the most FL CD3 low Gating (n = 14) * Control (n = 15) CD3 medium Gating (n = 16) Figure 1 The abscissa shows the fluorescence intensity (FL), and the ordinate indicates the gating procedure. The mean FL of the CD3 low, CD3 medium, and healthy volunteer (control) populations are shown. The box for each population extends from the 25th to the 75th percentile, and the line in the middle of the box represents the median value. No statistically significant difference in the mean FL was observed between the control and CD3 medium populations. The mean FL for the CD3 low population was significantly lower than that for the control population. * P <.001. P =.037. common single T-cell antigen abnormality, occurring in 6 cases (38%) in the CD3 medium population and in all cases (100%) in the CD3 low population. Coexpression of CD4 and CD8 occurred in 8 cases (50%) in the CD3 medium population but did not occur in the CD3 low population. Coexpression of CD45RO and CD45RA occurred in 6 cases (43%) in the CD3 medium population and 1 case (7%) in the CD3 low population. Regarding differences between the CD3 medium and CD3 low populations, there was no significant difference in the expression of CD2, CD4, CD5, CD28, CD62L, CD45RA, CD45RO, and HLA-DR. However, the expression levels of CD7 and CD8 in the CD3 low population were significantly lower than those in the CD3 medium population (P <.001 and P <.04, respectively) and expression of CD25 in the CD3 low population was significantly higher than that in the CD3 medium population (P <.01) Figure 2. Am J Clin Pathol 2005;124: DOI: /KEN4MXM5Y9A1GEMP 201
4 Yokote et al / ATLL IMMUNOPHENOTYPING USING CD3 GATING Table 1 Immunophenotyping of Adult T-Cell Leukemia/Lymphoma Specimens * Case No. Sample Type CD7 CD5 CD2 CD4 CD8 CD25 CD28 CD62L CD45RA CD45RO HLA-DR 1 PB PB PB BM BAL ND + + ND ND ND ND 6 LN ND ND ND ND 7 LN LN PB PB PB PB PB BM BM PL PB + + ND ND LN LN PB PB PB PB PB PB PB PB PB PB PB BAL, bronchoalveolar lavage fluid; BM, bone marrow; LN, lymph node; ND, not done; PB, peripheral blood; PL, pleural effusion; +, positive;, negative. * The CD3 peak fluorescence intensity below 10 on the log scale is defined as CD3 low, an intensity between 10 and 100 as CD3 medium. Samples 1-16 were analyzed using CD3 medium gating, and samples were analyzed using CD3 low gating. Table 2 Summary of Immunophenotyping Using CD3 low and CD3 medium Gating * Immunophenotype CD3 low Gating CD3 medium Gating CD7 0/14 (0) 10/16 (63) CD5 13/14 (93) 15/15 (100) CD2 13/14 (93) 15/15 (100) CD4 11/12 (92) 16/16 (100) CD8 1/12 (8) 8/16 (50) CD25 10/14 (71) 3/16 (19) CD28 13/14 (93) 10/14 (71) CD62L 14/14 (100) 12/15 (80) CD45RA 3/14 (21) 6/14 (43) CD45RO 11/14 (79) 13/14 (93) HLA-DR 5/14 (36) 10/15 (67) * Data are given as number of positive cases/total number of cases (percentage of positive cases). Immunohistochemical Analysis Immunohistochemical analysis using CD7, CD4, and CD8 was performed for all samples. The ATLL cells in all specimens were not immunoreactive with CD7. In all specimens but one, the ATLL cells were immunoreactive with CD4 and were not immunoreactive with CD8. In the 1 aberrant case, for which flow cytometric analysis indicated the presence of a CD3 low population, the ATLL cells were immunoreactive with CD8 and were not immunoreactive with CD4. Because CD8+ and CD4 ATLL has been reported, 2,3 we did not conclude that this case should be categorized as having an inconclusive phenotype. The results of immunohistochemical analysis with CD7, CD4, and CD8 were consistent with immunophenotyping performed by flow cytometric analysis with CD3 low gating. In contrast, immunohistochemical analysis performed with CD7, CD4, and CD8 was inconsistent with the flow cytometric analysis using the CD3 medium gating procedure, suggesting that this procedure might not exclude normal T cells from ATLL cells. Discussion ATLL is a distinct clinicopathologic syndrome characterized by a mature T-cell surface marker profile, an association with HTLV-1, the presence of abnormal lymphocytosis with pleomorphic nuclei, 4-6 and clinical and cytogenetic diversity. 4,7-9 The abnormal lymphocytes typically express CD2, CD3, CD4, CD5, and CD25; rarely express CD8; and lack CD7 expression in immunophenotypic analysis. 10,11 Because the morphologic 202 Am J Clin Pathol 2005;124: DOI: /KEN4MXM5Y9A1GEMP
5 Hematopathology / ORIGINAL ARTICLE * 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% CD7 CD5 CD2 CD4 CD8 CD25 CD28 CD62L CD45RA CD45RO HLA-DR Figure 2 There was no significant difference in the expression of CD2, CD4, CD5, CD28, CD62L, CD45RA, CD45RO, and HLA- DR. The expression of CD7 and CD8 in the CD3 low gating population (black bars) was significantly lower than that in the CD3 medium gating population (white bars), and CD25 expression in the CD3 low gating population was significantly higher than that in the CD3 medium gating population. * P <.001. P <.04. P <.01. features of ATLL are diverse, confirmation of the presence of the disease is obtained through use of a specific antibody panel for immunocytochemical analysis, and flow cytometry can be used to help distinguish ATLL from other peripheral T-cell lymphoproliferative diseases, such as T-cell prolymphocytic leukemia, certain kinds of peripheral T-cell lymphoma, and mycosis fungoides/sézary syndrome. 10 The expression of CD2, CD3, CD4, CD8, CD25, CD28, CD45RA, CD45RO, and HLA-DR on ATLL cells has been reported, but these data are based on immunophenotyping combined with flow cytometric analysis using a conventional gating step for forward scatter and SS or on immunohistochemical analysis Flow cytometric analysis has been introduced to study hematologic malignancy based on surface antigen levels, because malignant cells often display an aberrant phenotype, which may involve antigen loss or changes in combinations of surface markers, compared with normal hematologic cells. However, most T-cell antigens are expressed on normal and abnormal T lymphocytes. Hence, it is difficult to discriminate between normal and abnormal T cells by a conventional immunophenotyping strategy 17 because the conventional gating step for forward scatter and SS does not discriminate well between such cells. In acute myeloid leukemia, good discrimination can be achieved between the blast cell population and normal cells through the systematic use of leukocyte common antigen (CD45) expression and SS. 18 This discrimination is based on the fact that the precursor cells express low and intermediate levels of CD45, whereas mature lymphocytes express a high level of CD However, because ATLL is a lymphoproliferative disease of peripheral T-cell origin, the ATLL cells partially overlap with the gated normal lymphocytes, and, therefore, this procedure cannot discriminate between normal and ATLL cells. CD3 is part of the T-cell receptor complex and is involved in transducing stimulatory signals after antigen-specific recognition. 20 It is expressed in the membrane at the late stage of thymic differentiation and in mature (peripheral) T lymphocytes, 21 after which CD3 can be detected only in the cytoplasm at the earliest stages of T-cell differentiation. The expression of CD3 is down-regulated after antigen recognition and activation. 22 Similarly, ATLL cells are activated T cells that mostly express interleukin-2 receptor (CD25), and it has been suggested that CD3 is down-regulated in ATLL cells after activation and infection with HTLV-1. 23,24 Therefore, we anticipated that good discrimination between normal T cells and ATLL cells might be achieved through the use of CD3 expression. The revised European-American Lymphoma (REAL) classification is in widespread use. This system emphasizes immunophenotyping analysis with clinical features and morphologic criteria. In the REAL classification, ATLL is placed in the category of peripheral T-cell and natural killer cell neoplasms. Tumor cells typically express CD2, CD3, CD4, CD5, and CD25; rarely express CD8; and usually lack CD7, based on immunophenotypic analysis. 10,11 Immunophenotyping performed by flow cytometric analysis with CD3 low gating is largely consistent with the immunophenotyping criteria suggested in the REAL classification, 10 as previous reports also have stated We studied the immunophenotyping of ATLL by flow cytometric analysis with CD3 gating. Because statistically significant differences in immunophenotyping were apparent between CD3 low and CD3 medium gating, we compared the results Am J Clin Pathol 2005;124: DOI: /KEN4MXM5Y9A1GEMP 203
6 Yokote et al / ATLL IMMUNOPHENOTYPING USING CD3 GATING of flow cytometric analysis with immunohistochemical data for the expression of CD7, CD4, and CD8. Flow cytometric analysis is easy to perform, reliable, and inexpensive, and clinically relevant data can be obtained soon after completion of flow cytometry measurements. The CD3 low gating procedure is more sensitive than conventional or CD45/SS gating and seems to be an appropriate method of choice. The clinical course of ATLL is very aggressive, 25,26 but recently it has been suggested that the disease might be cured by allogeneic stem cell transplantation. 25 We also believe that minimal residual disease monitoring is clinically useful during follow-up after therapy. If specific surface markers in ATLL cells are determined, flow cytometric assays can efficiently complement techniques for minimal residual disease monitoring, particularly in combination with studies of T-cell receptor gene rearrangement. From the 1 First Department of Internal Medicine, 2 Division of Surgical Pathology, and 3 Department of Clinical Central Laboratory, Osaka Medical College, Osaka, Japan. Address reprint requests to Dr Yokote: First Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka , Japan. References 1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group ( ). Br J Haematol. 1991;79: Matsushita K, Arima N, Hidaka S, et al. CD8-positive adult T-cell leukemia cells with an integrated defective HTLV-I genome show a paracrine growth to IL-2. Am J Hematol. 1994;47: Lorand-Metze I, Pombo-de-Oliveira M. Adult T-cell leukemia (ATL) with unusual immunophenotype and a high cellular proliferation rate. Leuk Lymphoma. 1996;22: Uchiyama T, Yodoi J, Sasagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50: Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981;78: Yoshida M, Seiki M, Yamaguchi K, et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A. 1984;81: Kikuchi M, Mitsui T, Takeshita M, et al. Virus-associated adult T-cell leukemia (ATL) in Japan: clinical, histological and immunological studies. Hematol Oncol. 1986;4: Duggan DB, Ehrlich GD, Davey FP, et al. HTLV-I-induced lymphoma mimicking Hodgkin s disease; diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA. Blood. 1988;71: Itoyama T, Chaganti RS, Yamada Y, et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood. 2001;97: Harris NL, Jaffe ES, Stein H, et al. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: Dahmoush L, Hijazi Y, Barnes E, et al. Adult T-cell leukemia/ lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study. Cancer. 2002;96: Suzuki M, Uno H, Yamashita K, et al. Clinical significance of CD45RO expression on peripheral blood mononuclear cells in HTLV-I infected individuals. Br J Haematol. 1996;92: Worner I, Matutes E, Beverley PC, et al. The distribution of CD45R, CD29 and CD45RO (UCHL1) antigens in mature CD4 positive T-cell leukaemias. Br J Haematol. 1990;74: Richardson JH, Edwards AJ, Cruickshank JK, et al. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol. 1990;64: Nagatani T, Matsuzaki T, Iemoto G, et al. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma: clinical, histopathologic, and immunohistochemical analyses. Cancer. 1990;66: Shirono K, Hattori T, Hata H, et al. Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood. 1989;73: Ginaldi L, Matutes E, Farahat N, et al. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol. 1996;93: Borowitz MJ, Guenther KL, Shults KE, et al. Immunophenotyping of acute leukemia by flow cytometric analysis: use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol. 1993;100: Shah VO, Civin CI, Loken MR. Flow cytometric analysis of human bone marrow, IV: differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol. 1988;140: Meuer SC, Acuto O, Hussey RE, et al. Evidence for the T3- associated 90K heterodimer as the T-cell antigen receptor. Nature. 1983;303: Reinherz EL, Kung PC, Goldstein G, et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A. 1980;77: Beverley P. The importance of T3 in the activation of T lymphocytes. Nature. 1983;304: Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79: Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest. 1985;76: Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T-cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27: Yamada Y, Tomonaga M, Fukunaga H, et al. A new G- CSF supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study Br J Haematol. 2001;113: Am J Clin Pathol 2005;124: DOI: /KEN4MXM5Y9A1GEMP
Case 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
More informationAberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation
Hematopathology / CD7 Expression and FLT3/ITD Mutation in AML Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3/ITD Mutation Veronica Rausei-Mills,
More informationVUmc Basispresentatie
Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationFlow cytometric evaluation of endoscopic biopsy specimens from patients with gastrointestinal tract B-cell lymphoma: a preliminary report
Jichi Medical University Journal Flow cytometric evaluation of endoscopic biopsy specimens from patients with gastrointestinal tract B-cell lymphoma: a preliminary report Satoko Oka,, Kazuo Muroi,, Kazuya
More informationSignificant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow
Hematopathology / CD5 Expression on Normal B Cells Significant CD5 Expression on Normal Stage 3 Hematogones and Mature B Lymphocytes in Bone Marrow Franklin S. Fuda, DO, Nitin J. Karandikar, MD, PhD, and
More informationLevels of expression of CD19 and CD20 in chronic B cell leukaemias
364 Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, London SW3, UK E Matutes N Farahat R Morilla D Catovsky Department of Internal Medicine,
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationImmunophenotyping in the diagnosis of chronic lymphoproliferative disorders
J7 Clin Pathol 1994;47:871-875 871 L eaders~~~~~~~~~~~~~~~~.........;->:>> :*--:-- :- -::-*;:- --::- >:-:;-:: ::;...:::::...::::::::::*::;:;;::;::;::;;:;;:;;::;::;::;;:;;:;:::::::::::::::::: Task Force
More informationEstablishing a Pure Lymphocyte Gate for Subset Analysis by Flow Cytometry
Cytornetry (Communications in Clinical Cytometry) 26:172-177 (1996) Establishing a Pure Lymphocyte Gate for Subset nalysis by Flow Cytometry Joseph M. Homtinovich, Sara D. Sparks, and Karen P. Mann Clinical
More informationIKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1
Supplemental Figures BLOOD/2014/547943 IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1 Hsieh M-Y and Van Etten RA Supplemental Figure S1. Titers of retroviral
More informationPeripheral blood Pleural effusion in a cat
Tools for the Diagnosis of Lymphoproliferative Diseases When is it difficult to diagnose lymphoproliferative disease? Persistent lymphocytosis consisting of small Lymph node aspirates containing an excess
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationIntraocular Invasion of Adult T-Cell Leukemia Cells without Systemic Symptoms after Cataract Surgery
Published online: November 16, 2013 1663 2699/13/0043 0252$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC)
More informationLeukemic Phase of Mantle Cell Lymphoma, Blastoid Variant
Hematopathology / LEUKEMIC BLASTOID MANTLE CELL LYMPHOMA Leukemic Phase of Mantle Cell Lymphoma, Blastoid Variant Timothy P. Singleton, MD, Margaret M. Anderson, MD, Charles W. Ross, MD, and Bertram Schnitzer,
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationHematology MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL*
Hematology FREQUENCY OF ABERRANT EXPRESSION OF CD MARKERS IN CASES OF ACUTE LEUKEMIA MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL* SUMMARY: In the present study 100 patients
More informationComparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies
Malaysian J Pathol 2004; 26(2) : 111 116FLOW CYTOMETRY MYELOPEROXIDASE DETECTION Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies CF Leong MPath,
More informationCME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1.
Hematopathology / New Mastocytosis Flow Cytometry Approach High-Sensitivity Flow Cytometric Analysis for the Evaluation of Systemic Mastocytosis Including the Identification of a New Flow Cytometric Criterion
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014)
More information2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228
2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07
More informationLack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral B-Cell Lymphoma
Hematopathology / SURFACE IMMUNOGLOBULIN LIGHT CHAIN NEGATIVE PERIPHERAL B-CELL LYMPHOMA Lack of Surface Immunoglobulin Light Chain Expression by Flow Cytometric Immunophenotyping Can Help Diagnose Peripheral
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationMantle Cell Lymphoma
HEMATOPATHOLOGY Original Article Mantle Cell Lymphoma Morphologic Findings in Bone Marrow Involvement JAY WASMAN, MD, 1 NANCY S. ROSENTHAL, MD,' AND DIANE C. FARHI, MD 2 Although mantle cell lymphoma (MCL),
More informationSuccessful flow cytometric immunophenotyping of body fluid specimens
Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2
More informationAdult T-cell Leukemia/Lymphoma with a Giant Gastric Tumor: A Case Report
Adult T-cell Leukemia/Lymphoma with a Giant Gastric Tumor: A Case Report Shungo Hiroyasu, Masayuki Shiraishi, Masamori Shimabukuro, Toshiomi Kusano and Yoshihiro Muto First Department of Surgery, School
More informationThe properties of CD45/ SS in the blast Population of AML Sudanese patients
EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 6/ September 2015 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) The properties of CD45/ SS in the blast Population of AML
More informationCME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens
Hematopathology / Flow Cytometric Immunophenotyping of CSF Specimens Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Fiona E. Craig, MD, 1 N. Paul Ohori, MD, 2 Timothy S. Gorrill, MD,
More informationFLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis
FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis David M. Dorfman, MD, PhD, Charlotte D. LaPlante, Olga Pozdnyakova, MD, PhD, and Betty
More informationOriginal Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3):
Open Access Original Article Acute Leukemias And Aberrant Markers Expression Pak Armed Forces Med J 2018; 68 (3): 450-54 SPECTRUM OF ACUTE LEUKEMIAS AND ABERRANT MARKERS EXPRESSION BASED ON FLOWCYTOMETRY
More informationJMSCR Vol. 03 Issue 06 Page June 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x An Indolent Natural Killer Cell Leukemia Presenting with Bilateral Ankle Arthritis and Low Grade Fever Abstract Author Subhash Chandra
More informationCritical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry
Hematopathology / FLOW CYTOMETRIC IMMUNOPHENOTYPING IN B-CELL NON-HODGKIN LYMPHOMA Critical Analysis and Diagnostic Usefulness of Limited Immunophenotyping of B-Cell Non-Hodgkin Lymphomas by Flow Cytometry
More informationMultidimensional Flow Cytometry for Detection of Rare Populations in Hematological Malignancies
TZU CHI MED J March 2009 Vol 21 No 1 available at http://ajws.elsevier.com/tcmj Tzu Chi Medical Journal Original Article Multidimensional Flow Cytometry for Detection of Rare Populations in Hematological
More informationThe patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:
Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-
More informationT CELL LYMPHOMA ANALYSIS
T CELL LYMPHOMA ANALYSIS Charles Goolsby, Ph.D. Floyd E. Patterson Research Professor of Pathology Northwestern Feinberg School of Medicine c-goolsby@northwestern.edu 1 T CELL LYMPHOMA ANALYSIS Diverse
More informationPersistent lymphocytosis. Persistent lymphocytosis: are there prognostic indicators? Problem. Questions. Basic markers used to identify lymphocytes
Persistent lymphocytosis Persistent lymphocytosis: are there prognostic indicators? Paul R. Avery VMD, PhD, DACVP Marjorie Williams, DVM Anne C. Avery VMD, PhD Clinical Immunology Laboratory Colorado State
More informationFlow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia
Hematopathology / CD5+ -CELL NLYSIS Y FLOW CYTOMETRY Flow Cytometric nalysis of CD5+ Cells Frame of Reference for Minimal Residual Disease nalysis in Chronic Lymphocytic Leukemia Ritu Gupta, MD, 1 Paresh
More informationFlow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies
Hematopathology / Light Chain Expression in B-NHLs Flow Cytometric Analysis of Surface Light Chain Expression Patterns in B-Cell Lymphomas Using Monoclonal and Polyclonal Antibodies Pedro Horna, MD, Horatiu
More informationTest Definition: LCMS Leukemia/Lymphoma Immunophenotyping by Flow Cytometry
Reporting Title: Leukemia/Lymphoma, Phenotype Performing Location: Rochester Advisory Information: This test is appropriate for hematopoietic specimens only. If your specimen is a solid tissue, order LLPT
More informationUnknown Case 6. Ann T. Moriarty, MD
Unknown Case 6 Ann T. Moriarty, MD Unknown Case 6 61 year old male with an enlarged cervical lymph node. He has a history of lung carcinoma, renal cell carcinoma and lymphoma. Case 6 Image 1: Fine needle
More informationSummary. Conclusions Our results show a close correlation between clinicopathological features of HTLV-I-associated cutaneous lesions and prognosis.
CLINICAL AND LABORATORY INVESTIGATIONS DOI 1.1111/J.1365-2133.24.6274.X Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma T. Yamaguchi,* K. Ohshima,* K. Karube,* T.
More informationDiagnostic Usefulness of CD23 and FMC-7 Antigen Expression Patterns in B-Cell Lymphoma Classification
Hematopathology / AND ANTIGEN EXPRESSION IN B-CELL LYMPHOMA CLASSIFICATION Diagnostic Usefulness of and Antigen Expression Patterns in B-Cell Lymphoma Classification Diana P. Garcia, MD, 1* Michele T.
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationImmunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Hematopathology / IMMUNOPHENOTYPE OF LPL/WM Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Sergej Konoplev, MD, PhD, L. Jeffrey Medeiros, MD, Carlos E. Bueso-Ramos,
More informationDiagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation
Case Study Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Ling Wang 1 and Xiangdong Xu 1,2,* 1 Department of Pathology, University of California, San Diego; 2
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationDo Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine
Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity
More informationCME/SAM. Abstract. Hematopathology / CD103 and CD123 in B-Cell Neoplasia
Hematopathology / CD103 and CD123 in B-Cell Neoplasia Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia Usefulness of CD123 and CD103 in the Diagnosis of Mature B-Cell Lymphoproliferative
More informationLymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients
Hematopathology / LYMPHOMAS WITH IGM PARAPROTEIN Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Pei Lin, MD, 1 Suyang Hao, MD, 1* Beverly C. Handy, MD, 2 Carlos E. Bueso-Ramos,
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationTerminal Deoxynucleotidyl Transferase Positive Cells in Human Tonsils
Hematopathology / TDT-POSITIVE TONSIL CELLS Terminal Deoxynucleotidyl Transferase Positive Cells in Human Tonsils James A. Strauchen, MD, and Lorraine K. Miller, PhD Key Words: Terminal deoxynucleotidyl
More informationCCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma
AJCP /CASE REPORT CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma Yuan Miao, MD, 1,2 Pei Lin, MD, 1 Wei Wang, MD, 1 L. Jeffrey Medeiros, MD,
More informationABERRANT EXPRESSION OF CD19 AND CD43
ABERRANT EXPRESSION OF CD19 AND CD43 IN A PATIENT WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND A HISTORY OF MANTLE CELL LYMPHOMA Yen-Chuan Hsieh, 1 Chien-Liang Lin, 2 Chao-Jung Tsao, 2 Pin-Pen Hsieh,
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationAnaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases
Hematopathology / FLOW CYTOMETRY OF ANAPLASTIC LYMPHOMA Anaplastic Large Cell Lymphoma A Flow Cytometric Analysis of 29 Cases Melissa V. Kesler, MD, Geeta S. Paranjape, MD, Sheryl L. Asplund, MD, Robert
More informationDr Prashant Tembhare
Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationCME/SAM. Mixed Phenotype Acute Leukemia
AJCP / Original Article Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria Olga K. Weinberg,
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationT-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3
Case Study J Clin Exp Hematop Vol. 55, No. 1, June 2015 T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis Yuriko Yoshioka,
More informationReactive and Neoplastic Lymphocytosis
Reactive and Neoplastic Lymphocytosis Koranda A. Walsh, VMD, BS Assistant Professor, Clinical Pathobiology University of Pennsylvania School of Veterinary Medicine PLEASE NOTE: These notes are meant as
More informationThe development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory
The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell
More informationLymphocyte Subpopulations in Peripheral Blood and the Spleen from Gastric Cancer Patients
Hiroshima J. Med. Sci. Vol.39, No.2, 23-27, June, 1990 HIJM 39-6 23 Lymphocyte Subpopulations in Peripheral Blood and the Spleen from Gastric Cancer Patients Katsumasa KUROI, Yukio SATO, Takahiko TAKAYAMA,
More informationFlow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma
Flow Cytometric Analysis of Cerebral Spinal Fluid Involvement by Leukemia or Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI, NIH DEPARTMENT OF
More informationThe spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More informationADx Bone Marrow Report. Patient Information Referring Physician Specimen Information
ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS
More informationClinical question. Screening tube. Diagnostic panel MRD. Clinical question
OW CYTOMETRY UPDATES IN LYMPHOPROLIFERATIVE DISORDERS CANCER RESEARCH CENTER IBSAL UNIVERSITY & UNIVERSITY HOSPITAL, SALAMANCA (SPAIN) DISCLOSURES The EuroFlow Scientific Consortium Iamco-chairof receives
More informationFLOW CYTOMETRIC ANALYSIS OF NORMAL BONE MARROW
XI International Conference Hematopoiesis Immunology Budapest, June 6-7, 2014 FLO CYTOMETRIC ANALYSIS OF NORMAL BONE MARRO Bruno Brando and Arianna Gatti Hematology Laboratory and Transfusion Center Legnano
More informationWelcome. Welcome. Emerging Technologies in Flow Cytometry
Emerging Technologies in Flow Cytometry Dr. William Dittman December 11, 2012 You may download a copy of the handout by clicking on the handout icon, located in the upper right hand corner of your screen
More informationImmunophenotyping in the diagnosis of acute leukaemias
J Clin Pathol 1994;47:777-781 777....':'. I.......-.......... Leader... Task Force Members R M Rowan (Chair) B J Bain (Secretary) J M England K Hyde E Matutes J T Reilly A D Stephens S M Lewis N K Shinton
More informationFLOW CYTOMETRY PRINCIPLES AND PRACTICE. Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018
FLOW CYTOMETRY PRINCIPLES AND PRACTICE Toby Eyre Consultant Haematologist Oxford University Hospitals NHS Foundation Trust June 2018 Aims and Objectives Principles of flow cytometry Preparation Steps involved
More informationHEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain
More informationDepartment of Veterinary Pathology, University of Milan, Italy
Chronic lymphocytic leukemia/small cell lymphoma in a horse Cian F 1, Tyner G 2, Martini V 3, Comazzi S 3, Archer J 1 1 Department of Veterinary Medicine, University of Cambridge, UK 2 Chiltern Equine
More informationFrom Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
More informationGray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres
Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Treseler, MD, PhD University of California San Francisco
More informationImmunophenotypic study of acute leukemia by flow cytometry at BPKMCH.
Nepal Medical Association Building Exhibition Road, Kathmandu Journal of Pathology of Nepal (2013) Vol. 3, 345-350 Association of Clinical Pathologist of Nepal-2010 Journal of PATHOLOGY of Nepal www.acpnepal.com
More informationMorphologic and Immunopathologic Spectrum of Malignant Lymphoma: Review of 211 Cases
Morphologic and Immunopathologic Spectrum of Malignant Lymphoma: Review of 211 Cases M. Ashraf Ali, MD, FRCP(C); Mohammed Akhtar, MD; Magid Amer, MD, FRCS From the Department of Pathology and Laboratory
More informationIntegrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationNaive, memory and regulatory T lymphocytes populations analysis
Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis
More informationImmunophenotyping of lymphoproliferative disorders: state of the art
Pathology (December 2005) 37(6), pp. 457 478 PRACTICAL ASPECTS OF DIAGNOSTIC HISTOPATHOLOGY Immunophenotyping of lymphoproliferative disorders: state of the art EMMA J. GUDGIN AND WENDY N. ERBER Haematology
More informationMATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All
MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationGastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR
Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR Pages with reference to book, From 305 To 307 Irshad N. Soomro,Samina Noorali,Syed Abdul Aziz,Suhail Muzaffar,Shahid
More informationCase Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent
Int J Clin Exp Med 2014;7(1):307-311 www.ijcem.com /ISSN:1940-5901/IJCEM1311029 Case Report A case of EBV positive diffuse large B-cell lymphoma of the adolescent Qilin Ao 2, Ying Wang 1, Sanpeng Xu 2,
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationCitation Acta Medica Nagasakiensia. 1989, 34
NAOSITE: Nagasaki University's Ac Title Clinical Features of Adult T-cell L Author(s) Ichimaru, Michito Citation Acta Medica Nagasakiensia. 1989, 34 Issue Date 1989-03 URL http://hdl.handle.net/10069/17540
More informationTel: Fax: Received: 25, Jul, 2014 Accepted: 16, Dec, 2014
IJHOSCR International Journal of Hematology- Oncology and Stem Cell Research Original Article T-cell/Natural killer-cell neoplasms presenting as leukemia- Case series from single tertiary care center Shano
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationAcute Lymphoblastic Leukemia in Elderly Patients The Philadelphia Chromosome May Not Be a Significant Adverse Prognostic Factor
Hematopathology / ACUTE LYMPHOBLASTIC LEUKEMIA IN ELDERLY PATIENTS Acute Lymphoblastic Leukemia in Elderly Patients The Philadelphia Chromosome May Not Be a Significant Adverse Prognostic Factor Mihaela
More informationSupplementary Table; Supplementary Figures and legends S1-S21; Supplementary Materials and Methods
Silva et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Supplementary Table; Supplementary Figures and legends S1-S21; Supplementary
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationCD5~ Small B-Cell Leukemias Are Rarely Classifiable as Chronic Lymphocytic Leukemia
Hematopathology / CD5- LYMPHOPROLIFERATIVE DISORDERS CD5~ Small B-Cell Leukemias Are Rarely Classifiable as Chronic Lymphocytic Leukemia Jane C. Huang, M D, William G. Finn, M D, Charles L. Goolsby, PhD,
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationMultiparameter flow cytometry can be used to
Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School
More information